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Stevens-Johnson syndrome (SJS) and toxic epidermal
necrolysis (TEN), defined by widespread blisters aris-
ing on macules and/or flat atypical targets, are dis-
eases with homogenous clinical characteristics and 
a potentially lethal outcome [1]. SJS is usually associ-
ated with some types of anticonvulsants, including
carbamazepine, lamotrigine, phenobarbital, phenyt-
oin and valproic acid [2]. A new anticonvulsant,
oxcarbazepine, which is structurally related to carba-
mazepine (CBZ), was introduced for use in patients
with epilepsy. According to a review of the literature,
it appears that oxcarbazepine-induced SJS has been
rarely reported [3]. Recently, Chung et al found a
strong association between human leukocyte antigen
(HLA) B*1502 and CBZ-induced SJS/TEN in the Han
Chinese population [4]. Here, we report a rare case 
of oxcarbazepine-induced SJS and review the related
literature. In addition, HLA typing was investigated
in this patient and the significance is discussed.
CASE PRESENTATION
The patient studied was 9 years old at his first visit 
to the Department of Pediatrics, Kaohsiung Medical
University Hospital. He was the third child of noncon-
sanguineous parents. Pregnancy, gestation, delivery
and birth weight were all normal. His development
was unremarkable. His first seizure occurred when
he was 6 months old and the patient then took anti-
convulsant with phenytoin for several months. When
no further seizure attacks were noted, phenytoin was
withdrawn.
However, seizure occurred again and he was
brought to our outpatient department. His seizure
was characterized by clonic movement of his hands
and legs, with loss of consciousness. Physical exami-
nation was unremarkable. The results of an electroen-
cephalogram revealed unremarkable findings. At that
time, oxcarbazepine, 300mg/day, was prescribed. One
week later, the dose of oxcarbazepine was increased to
600 mg/day. Unfortunately, high fever and multiple
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Although carbamazepine (CBZ) is the most common cause of Stevens-Johnson syndrome (SJS), 
a new anticonvulsant, oxcarbazepine, which is structurally related to carbamazepine, has been shown
to induce SJS, although extremely rarely. Recently, a strong association was found between human
leukocyte antigen (HLA) B*1502 and CBZ-induced SJS/TEN in a Han Chinese population. Here,
we report a case with SJS, which was induced by oxcarbazepine. HLA genotyping in the patient
showed HLA-B*1518/B*4001. HLA-B*1518 is a HLA-B15 variant. The genetic significance of
HLA-B*1518 in association with oxcarbazepine-induced SJS needs to be further studied.
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maculopapule rashes were found over the patient’s
face and thigh initially on the 14th day after taking
oxcarbazepine. Two days later, some blisters were also
observed on his thigh. Then, multiple oral ulcers and
hyperemic conjunctivae were also noted (Figure 1).
He was brought to our emergency department
and admitted under the presumed diagnosis of SJS.
Laboratory investigations showed leukocytosis (WBC,
13,930/μL; reference value, 4,000–10,000/μL), and ele-
vated C-reactive protein (50.59μg/mL; reference range,
0–5 μg/mL).
After obtaining informed consent, we carried out
genotyping and took photos of the patient. HLA geno-
typing showed HLA-B*1518/B*4001. Askin biopsy was
also performed. The layer stratum corneum appeared
to be normal. There was marked liquefactive degen-
eration in the lower half of the epidermis with some
dyskeratotic keratinocytes. The dermis showed pre-
dominant CD8+ lymphohistiocytic infiltration around
the blood vessels and scanty eosinophils (Figure 2).
The skin pathology finding was consistent with SJS.
After steroid and antihistamine treatment for 7 days,
the patient improved and was discharged in a good
general condition 12 days later.
DISCUSSION
The diagnosis of SJS is based on clinical manifestations
with acute onset of rapidly expanding targetoid ery-
thematous macules, necrosis and detachment of the
epidermis along with erythema, erosions and crust-
ing of two or more mucosal surfaces [5]. The patients
usually develop a hypersensitivity reaction between
2 and 12 weeks after starting medicine [6]. Our patient
had skin targetoid erythematous rashes and mucosa
involvement 2 weeks after starting oxcarbazepine treat-
ment. During these 2 weeks, he took no medicine 
except for oxcarbazepine. The skin pathology finding
revealed lymphohistiocytic infiltration around the
blood vessels and scanty eosinophils, which was con-
sistent with SJS.
In this case, during the first week, we used 7.5 mg/
kg/day oxcarbazepine for seizure control, and then
increased the dose to 15 mg/kg/day. Both the initial
and titration doses were slightly lower than the rec-
ommended doses (15–45 mg/kg/day). It has been
reported that higher daily doses of drugs are associ-
ated with increased risk of SJS than lower doses,
which is the case for allopurinol [7]. However, there
is no evidence about the relationship between oxcar-
bazepine dosage and SJS.
Although many factors have been proposed as risk
factors of SJS, including adverse drug effects, malig-
nant disorders or graft-versus-host disease and infec-
tions, most of them were induced by drugs. The most
common drugs are anticonvulsants, particularly CBZ
[8]. In Taiwan, CBZ is the leading cause and accounts
for 25% of all cases of drug-induced SJS/TEN [4]. To
our knowledge, there are no reports of a Taiwanese
case of oxcarbazepine-induced SJS. According to the
Food and Drug Administration, the incidence of
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Figure 1. Skin and mucosa of our patient: (A) targetoid rashes over the right thigh; (B, C) conjunctivae and oral mucosa were 
involved by SJS.
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oxcarbazepine-induced SJS/TEN is estimated to range
between 0.5 and 6 cases per 1 million people per year
within the general population [9]. The incidence of
oxcarbazepine-induced SJS is estimated to be one in
every 10,000 exposures in Taiwan, while the incidence
of CBZ-induced SJS/TEN is estimated to be 1:2,000,
which is higher than that for oxcarbazepine-induced
SJS. The reason why oxcarbazepine has fewer side
effects is that oxcarbazepine is almost completely me-
tabolized through reduction and conjugation to yield
an active monohydroxy derivative. In contrast, the
oxidation of CBZ to 10,11-epoxide is regarded as the
most common cause of adverse effect [10]. Although
the pathogenesis of SJS remains unclear, Yang et al
reported that HLA-B*1502 represents an MHC mole-
cule that is strongly associated with CBZ-induced SJS/
TEN [11]. The fact that there is a nearly 100% association
of HLA-B*1502 with CBZ-induced SJS/TEN implies
that HLA-B*1502 is not only a genetic marker, but is
also a participant in the pathogenesis of SJS [11].
Considering that oxcarbazepine possesses a related
structure that might share a pathogenesis similar to
CBZ-induced SJS/TEN, we performed HLA geno-
typing on this patient. The results were HLA-B*1518/
B*4001. This differs from HLA-B*1502, although
HLA-B*1518 is still a HLA-B15 variant. In addition,
the allele frequency of HLA-B*1518 was only 0.5% in
Taiwanese Minnan. In an extended study, Chung et al
showed that some CBZ-induced SJS/TEN patients
who did not have the HLA-B*1502 gene had HLA-
B*1558, another HLA-B15 variant [12]. The role of
HLA-B*1518 in the immune reaction of SJS by oxcar-
bazepine is currently unclear because findings are
limited to a single case.
There is considerable debate about whether to treat
SJS with systemic steroids. However, Lam et al found
that the early use of short-term systemic steroids for
3–5 days lacked any significant side effects and did
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Figure 2. Microscopic findings of skin biopsy. (A, C) Low power field view shows tagging of lymphocytes along the dermoepidermal
junction and superficial perivascular lymphoid infiltrate in the lesion (areas between the arrows) (original magnification, 40×). (B, D)
High power field view shows abundant CD8 + lymphocytes approximating the dermoepidermal junction with vacuolization of the
basal cell layer (original magnification, 400×). (A, B: hematoxylin & eosin; C, D: CD8 immunohistochemical staining.)
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not increase mortality or morbidity in children [13].
Our patient was treated with intravenous steroid and
antihistamine for 7 days. He improved and was dis-
charged 12 days after admission. No sequelae were
found during 2 months of follow-up.
In conclusion, we have described the first case of
oxcarbazepine-induced SJS in Taiwan. The HLA typ-
ing of the patient is HLA-B*1518/B*4001. We need to
recruit more patients to elucidate the pathogenesis
and genetic markers of oxcarbazepine-induced SJS.
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Carbamazepine 是最常見引起史帝文 -強森症候群的一種藥物，另一種新的抗癲癇
藥物 -oxcarbazepine 雖然結構上跟 carbamazepine 類似，卻極少引起史帝文 -強
森症候群，最近在漢民族的研究顯示 carbamazepine 引起史帝文 -強森症候群是跟
人類白血球組織抗原 (human leukocyte antigen) HLA-B*1502 有強烈的相關性，
本篇文章報告一個由 oxcarbazepine 誘發史帝文 -強森症候群的病患，這個病患的人
類白血球組織抗原的檢驗結果為 HLA-B*1518/B*4001，而 HLA-B*1518 是 
HLA-B15 的異構體，因此 HLA-B*1518 在 oxcarbazepine 誘發史帝文 -強森症候
群的相關性還須進一步研究。
關鍵詞：oxcarbazepine，史帝文 -強森症候群
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